Market Overview
Global Cancer Gene Therapy Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
Cancer gene therapy is a promising field of medicine that uses genetic modification to treat cancer. It includes inserting genetic material into cancer cells to either directly kill them or increase their susceptibility to the immune system of the body. A vital tool for cancer researchers and physicians is cancer gene therapy, which includes cellular and gene therapies.
By directly killing cells, modulating the immune system, or fixing genetic defects to reverse the malignant state, nucleic acids can be transferred into the tumor or normal cells in cancer gene therapy to eradicate or minimize the tumor burden.
Market Scope
| Metrics | Details |
| CAGR | Significant Growth |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Technique, Therapy, Application, End-User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics:
Rising burden of cancer cases
The increasing cancer burden is expected to drive the market growth. The rising number of cancer cases is elevating and expanding the research and developmental activities. The rising prevalence of cancer also fuels the trend towards personalized medicine. A larger pool of potential patients with cancer creates a greater market opportunity for companies developing gene therapies. Gene therapy is a promising new method for treating non-small cell lung cancer.
For instance, according to the report published by the American Society of Cancer in 2024, it is estimated that lung cancer is the second most common cancer in both men and women in the United States.
Additionally, according to the report by the World Health Organization in 2022, it is estimated that around 2.3 million women are diagnosed with breast cancer and 670,000 deaths globally. Among women, breast cancer can strike at any age after adolescence and is more common in later life. Thus, the above factors are expected to drive the market growth.
High developmental and treatment costs
Gene therapy development and production is a costly and intricate procedure. This leads to heavy treatment costs, which could prevent many people from receiving it and put pressure on healthcare finances. The widespread adoption of these expensive medicines may be restricted by the reluctance of government programs, insurance providers, and hospitals to pay for them.
Market Segment Analysis
The global cancer gene therapy market is segmented based on technique, therapy, application, end-user and region.
Gene Induced Immunotherapy (GII) segment is expected to dominate the market growth
Gene induced immunotherapy segment is expected to hold the dominant position in the market share. This is due to the advantages of the procedure over other types. GII has the potential to be highly specific. By altering a patient's own immune cells to specifically target cancer antigens, gene-editing immunotherapy (GII) reduces the adverse effects associated with conventional medicines that could damage healthy cells.
GII provides a means of potentially eliciting a durable immune response against cancerous cells. Engineered immune cells can persist in the body and keep attacking cancer cells, potentially leading to durable remissions or even cures. GII medicines could be produced for different forms of cancer by targeting different antigens or by employing different gene editing techniques. Thus, the above factors are expected to drive the segment growth in the forecast period.
Market Geographical Share
North America is expected to hold a significant position in the cancer gene therapy market share
North America is expected to hold the dominant position in the market share. The region has a long history of substantial support for medical research, including studies on cancer. The National Cancer Institute (NCI) and other organizations are essential in providing financing and assistance for gene therapy research and development (R&D). North America's standing is further enhanced by the presence of notable institutions and research facilities.
For instance, according to the National Center for Science and Engineering Statistics in 2022, research and development spending by academic institutions totaled $97.8 billion in FY 2022, an increase of $8.0 billion from FY 2021. R&D expenditures funded by federal sources accounted for $4.9 billion of the total increase. Thus, increasing investments, funds and improved treatment options are expected to drive the region’s market growth.
COVID-19 Impact Analysis
During the early phases of the pandemic, numerous clinical trials for cancer gene therapy were postponed and discontinued. This was due to concerns about patient safety and the need to reallocate resources towards COVID-19 care. Approval and development of new gene therapies are slowed down by these hurdles. Research on COVID-19 has received funding that was intended for cancer research, including gene therapy.
Market Companies
The major global players in the market include Novartis AG, Gilead Sciences, Inc., Editas Medicine, Transgene SA, Amgen Inc., Sorrento Therapeutics, Inc., BioNTech SE., Cellectis, ALLOGENE THERAPEUTICS, Cabaletta Bio, Inc. among others.
Why Purchase the Report?
- To visualize the global cancer gene therapy market segmentation based on technique, therapy, application, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of cancer gene therapy market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global cancer gene therapy market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
